Trial Profile
A Phase III Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 15 Dec 2023 Status changed from active, no longer recruiting to completed.
- 12 Dec 2023 Results evaluating the long-term efficacy and safety of fostamatinib treatment and the off-therapy platelet count in Japanese patients with primary ITP , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 Apr 2023 Planned End Date changed from 1 Jan 2023 to 1 Sep 2023.